On Friday, the markets were higher on a strong jobs report, offsetting the Trump administration's $34 billion in tariffs placed on Chinese imports, and as China imposed its own tariffs on the U.S.
Jim Cramer: Which Animal Will Prevail, the Bulls or the Bears?
"What will decide things? I believe the earnings releases that start next week will be incredibly important given the push between tariffs and tens and twos versus employment. Any comment from the Fed Chairman that updates the thinking from last month about the disruption in world trade tempering hikes would help the bullish cause, too, but judging from the minutes yesterday that won't happen, so bring on the earnings to break the tie between the bulls and the bears," writes TheStreet's Jim Cramer.
Biogen: Let the Situation Cool Off a Bit Before Buying
"There are few diseases as cruel as Alzheimer's. I watched my mother deteriorate from it for years before she passed away from its ravages. Many others have had this experience so it was uplifting to see the headlines this morning that Biogen (BIIB - Get Report) and partner Eisai (ESALY) have announced positive Phase II results for a drug that treats Alzheimer's at an early stage," says Real Money columnist James DePorre.
"Despite the positive headlines there are issues in the study that are keeping some buyers cautious and causing selling into the early strength," DePorre points out.
4 Bargain-Priced Names for the Second Half
"As I wrote on Monday, the current market environment has many challenges," says Real Money Pro columnist Bret Jensen. "They include escalating imposition of trade tariffs, which we are reminded of yet again today as new tariffs are implemented on more than $30 billion of Chinese goods. This was sure to bring retaliation from the Middle Kingdom and potentially even higher volatility to the market. A brewing trade war is just one reason that I expect this to be a sideways market at best over the next few months."
"However, the challenges in the market do not mean there are not some bargains within equities that should hold up just fine and should even prosper despite what looks like a bumpy ride to start the second half of 2018," Jensen notes.